THREE MEMORANDA RE: NICOTINIC ACID WITH ATTACHED MEMOS

Document Type: 
Collection: 
Document Number (FOIA) /ESDN (CREST): 
00144761
Release Decision: 
RIPPUB
Original Classification: 
U
Document Page Count: 
4
Document Creation Date: 
November 22, 2024
Document Release Date: 
January 15, 1983
Sequence Number: 
Case Number: 
Publication Date: 
January 8, 1952
File: 
AttachmentSize
PDF icon THREE MEMORANDA RE NICOTI[12888070].pdf161.24 KB
Body: 
1 1 �� Chief, Contact Division for Scientific Branch Chief, Office Case erg, 8 January 1952 A/ 1. As recommended in Case , ve have discussed the uses of nicotinic acid and its compounds with 13 who is head of the Department of Pharmacology at the ) Medicil School in was most cooperative and made the following comments on the subject: 40, 2. The common use of nicotinic acid is as a vitamin; it is used principally as a preventative for pellagra (a skin affection with severe constitutional and nervous symptoms) in the southern part of the US. Its therapeutic action in these cases is in developing a psychosis and dilating the blood vessels. Li 3. Since nicotinic acid is a peripheral dilator of blood vessels, it might also be used in the treatment of frost bite but there is no published indication that this type of therapy has ever been developed anywhere. The staff of the Medical School Pharmacology Department has done much work on using a combination of nicotinomid with privine for the treatment of schizophrenic patients. Privine is a nicotinic acid inhibitor (B 45) and, although very lethal in animals, is not poisonous for human beings. The nicotinomid-privine combination produces a shock reaction iihidh does not involve convulsions. Experiments in this have beeh made an patients at - Hospital in "- . -----77but are no longer being carried on because of the lack of funds aad the difficulty in travel between the medical college laboratories and the hospital. C:: 5. did not knov of other doctors or laboratories in the US or abroad who were working with this nicotinomid-privine combina- tion or other nicotinic acid compounds. He could not recall having seen any publications on this subject. 6. This office believes that it might be advantageous to discuss 74/sr